Search results for "Isoxazole"

showing 10 items of 100 documents

Synthesis of Isoxazole and 1,2,3-Triazole Isoindole Derivatives via Silver- and Copper-Catalyzed 1,3-Dipolar Cycloaddition Reaction.

2016

International audience; The CuI-or Ag 2 CO 3-catalyzed [3+2] cycloaddition of propargyl-substituted dihydroisoindolin-1-one (3) with arylnitrile oxides 1a-d (Ar = Ph, p-MeC 6 H 4 , p-MeOC 6 H 4 , p-ClC 6 H 4) produces in good yields novel 3,5-disubstituted isoxazoles 4 of the ethyl-2-benzyl-3-oxo-1-((3-arylisoxazol-5yl)methyl)-2,3-dihydro-1H-isoindole-1-carboxylate type. With aryl azides 2a-d (Ar = Ph, p-MeC 6 H 4 , p-OMeC 6 H 4 , p-ClC 6 H 4), a series of 1,4-disubstituted 1,2,3-triazoles 6 (ethyl-2-benzyl-3-oxo-1-((1-aryl-1H-1,2,3-triazol-4-yl)methyl)-2,3-dihydro-1H-isoindole-1-carboxylates) was obtained. The reactions proceed in a regioselective manner affording exclusively racemic adduc…

123-TriazoleMagnetic Resonance SpectroscopySilverSpectrophotometry Infrared12Pharmaceutical Science[3+2] dipolar cycloaddition; arylnitrile oxides; arylazides; isoxazole; 123-triazolesarylazidesIsoindoles010402 general chemistryCrystallography X-Ray01 natural sciencesMedicinal chemistryCatalysisArticleAnalytical Chemistrylcsh:QD241-441chemistry.chemical_compoundlcsh:Organic chemistryDrug DiscoveryOrganic chemistryPhysical and Theoretical ChemistryIsoxazoleCycloaddition Reaction010405 organic chemistryArylOrganic ChemistryisoxazoleRegioselectivityIsoxazolesarylnitrile oxidesTriazolesCycloaddition0104 chemical scienceschemistryChemistry (miscellaneous)13-Dipolar cycloaddition[3+2] dipolar cycloadditionMolecular Medicine123-triazoles3-triazolesIsoindoleSelectivity[PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph]CopperMolecules (Basel, Switzerland)
researchProduct

SYNTHESIS AND ANTITUMOR ACTIVITY OF 2,5-BIS(3'-INDOLYL)-FURANS AND 3,5-BIS(3'-INDOLIY)-ISOXAZOLES, NORTOPSENTIN ANALOGUES

2010

Abstract A series of novel 2,5-bis(3′-indolyl)furans and 3,5-bis(3′-indolyl)isoxazoles were synthesized as antitumor agents. The antiproliferative activity was evaluated in vitro toward diverse human tumor cell lines. Initially 5 isoxazoles and 3 furan derivatives were tested against a panel of 10 human tumor cell lines and the most active derivatives 3c and 4a were selected to be evaluated in an extended panel of 29 cell lines. By exhibiting mean IC50 values of 17.4 μg/mL (3a) and 20.5 μg/mL (4c), in particular 4c showed a high level of tumor selectivity toward the 29 cell lines.

35-BIS(3'-INDOLIY)-ISOXAZOLESIndolesStereochemistry3Clinical Biochemistry2Pharmaceutical ScienceAntineoplastic AgentsBiochemistryChemical synthesis25-BIS(3'-INDOLYL)-FURANSchemistry.chemical_compound2; 5-BIS(3'-INDOLYL)-FURANS; 3; 5-BIS(3'-INDOLIY)-ISOXAZOLES; NORTOPSENTIN; ANTITUMOR ACTIVITYFuranCell Line TumorNeoplasmsDrug DiscoveryHumans5-BIS(3'-INDOLIY)-ISOXAZOLESCytotoxicityFurans5-BIS(3'-INDOLYL)-FURANSMolecular BiologyAntitumor activityAlkaloidOrganic ChemistryBiological activityNORTOPSENTINIsoxazolesSettore CHIM/08 - Chimica FarmaceuticaIn vitroANTITUMOR ACTIVITYchemistryCell cultureMolecular MedicineDrug Screening Assays Antitumor
researchProduct

CCDC 160805: Experimental Crystal Structure Determination

2001

Related Article: E.Aiello, S.Aiello, F.Mingoia, A.Bacchi, G.Pelizzi, C.Musiu, M.G.Setzu, A.Pani, P.La Colla, M.E.Marongiu|2000|Bioorg.Med.Chem.|8|2719|doi:10.1016/S0968-0896(00)00211-X

3-(5-Methyl-4-nitroso-1-propyl-1H-3-pyrazolyl)-5-methylisoxazoleSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Mossbauer spectroscopic study of the thermal spin crossover in [Fe(II)(isoxazole)(6)](ClO(4))(2)

2008

The (57)Fe Mossbauer spectroscopy of mononuclear [Fe(II)(isoxazole)(6)](ClO(4))(2) has been studied to reveal the thermal spin crossover of Fe(II) between low-spin (S = 0) and high-spin (S = 2) states.Temperature-dependent spin transition curves have been constructed with the least-square fitted data obtained from the Mossbauer spectra measured at various temperatures between 84 and 270 K during a cooling and heating cycle. This compound exhibits an unusual temperature-dependent spin transition behaviour with T(C)(down arrow) = 223 and T(C)(up arrow) = 213 K occurring in the reverse order in comparison to those observed in SQUID observation and many other spin transition compounds. The comp…

5-BIS(PYRIDIN-2-YL)-1Phase transitionMossbauer spectroscopySpin transition2Inorganic compoundsABPT=4-AMINO-3chemistry.chemical_compoundMOLECULESNuclear magnetic resonanceSpin crossoverMössbauer spectroscopyMagnetic propertiesPERCHLORATEGeneral Materials Science4-TRIAZOLEIsoxazoleSpin (physics)Mössbauer effectORDER-DISORDER PHENOMENABIS(3-AMINOPROPYL)(2-PYRIDYLMETHYL)AMINECOMPOUNDGeneral ChemistryAtmospheric temperature rangeCondensed Matter PhysicsSTATECrystallographychemistryPhase transitionsPHASE-TRANSITIONCondensed Matter::Strongly Correlated ElectronsCOMPLEXESLIGANDSABPT=4-AMINO-35-BIS(PYRIDIN-2-YL)-124-TRIAZOLEJournal of Physics and Chemistry of Solids
researchProduct

Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study

2009

Summary Purpose To report on the first multicenter Italian experience with zonisamide as an add-on drug for refractory generalised or partial epilepsy in children, adolescents and young adults. Methods The patients were enrolled in a prospective, add-on, open-label treatment study from eight Italian centres for children and adolescent epilepsy care. Eighty-two young patients (45 males, 37 females), aged between 3 and 34 years (mean 13.1 years), all affected by partial (47) or generalised (35) refractory epilepsy, were enrolled in the study. ZNS was added to the baseline therapy at a starting dose of 1 mg/kg/day twice daily. This dose was increased by 2 mg/kg every 1–2 weeks over a period of…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentAntiepileptic drugsZonisamideIrritabilityStatistics NonparametricEpilepsyYoung AdultRefractorymedicineHumansNonparametricYoung adultAdverse effectPreschoolChildNeurologic ExaminationEpilepsybusiness.industryStatisticsElectroencephalographyDrug ToleranceIsoxazolesmedicine.diseaseMagnetic Resonance ImagingSettore MED/39 - Neuropsichiatria InfantileEpilepsy; Zonisamide; Pediatric epilepsy; Antiepileptic drugsAnticonvulsantTolerabilityNeurologyItalyZonisamideChild PreschoolAnticonvulsantsFemaleNeurology (clinical)medicine.symptombusinessPediatric epilepsyAntiepileptic drugs; Epilepsy; Pediatric epilepsy; Zonisamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Tolerance; Electroencephalography; Epilepsy; Female; Follow-Up Studies; Humans; Isoxazoles; Italy; Magnetic Resonance Imaging; Male; Neurologic Examination; Statistics Nonparametric; Young Adult; Neurology; Neurology (clinical)medicine.drugFollow-Up Studies
researchProduct

Risperidone in the Treatment of Disorders with a combined Psychotic and Depressive Syndrome - A Functional Approach

1992

In vitro receptor-binding profiles and in vivo pharmacological studies have shown risperidone to be a potent mixed serotonin-S2 dopamine-D2-like receptor antagonist. While anti-D2 activity may relate to the antipsychotic potency of neuroleptic drugs, an antidepressive efficacy of substances with anti-S2 activity has been suggested. In an open pilot-study, ten patients with schizodepressive disorders or a DSM-III-R diagnosis of psychotic major depressive episodes were treated with risperidone (2-10 mg/d) for six weeks. Weekly psychopathological evaluation was performed, including BPRS, SANS, SAPS, VAS scales, and AIMS and UKU for the assessment of side-effects. Generally, the psychotic syndr…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPiperidinesInternal medicineHumansMedicinePotencyPharmacology (medical)AntipsychoticDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressive DisorderRisperidonebusiness.industryDopamine antagonistIsoxazolesSyndromeGeneral MedicineMiddle AgedRisperidoneReceptor antagonistBiperidenPsychiatry and Mental healthPsychotic DisordersAnesthesiaFemalebusinessAntipsychotic AgentsPsychopathologymedicine.drugPharmacopsychiatry
researchProduct

Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers

1993

Leflunomide (HWA 486), an isoxazol derivative, has been shown to be very effective in combating autoimmune diseases and transplantation rejection in a great number of animal models. The main metabolite of leflunomide, A77 1726, is a potent antiproliferative compound. To further elucidate this effect, lymphocytes of healthy human donors were cultured for 24, 48 or 72 h in the presence of PHA or immobilized anti-CD3 antibody. A77 1726 was added at concentrations between 10 and 100 microM. Flow cytometric evaluation of early activation or proliferation markers (IL-2 and transferrin receptors, respectively) showed that their expression was inhibited in a dose-dependent manner by A77 1726. Toget…

Adultmedicine.medical_specialtyAllergyToluidinesMetaboliteImmunologyHydroxybutyratesTransferrin receptorBiologyPharmacologyLymphocyte ActivationToxicologychemistry.chemical_compoundImmune systemInternal medicineNitrilesReceptors TransferrinmedicineHumansPharmacology (medical)PhytohemagglutininsLeflunomidePharmacologyAniline CompoundsAnti-Inflammatory Agents Non-SteroidalReceptors Interleukin-2Isoxazolesmedicine.diseaseRheumatologyTransplantationchemistryCrotonatesImmunologybiology.proteinAntibodyBiomarkersLeflunomidemedicine.drugAgents and Actions
researchProduct

Coupling between agonist and chloride ionophore sites of the GABA(A) receptor: agonist/antagonist efficacy of 4-PIOL.

2000

Eight gamma-aminobutyric acid (GABA) mimetics were tested on their ability to differentiate native GABA(A) receptor subtypes present in various rat brain regions. In rat brain cryostat sections, little regional variations by the agonistic actions of muscimol, thiomuscimol, 4,5,6,7-tetrahydroisoazolo(5,4-c)pyridin-3-ol, piperidine-4-sulphonic acid, taurine and beta-alanine on [35S]t-butylbicyclophosphorothionate ([35S]TBPS) binding to GABA(A) receptor channels were found. They were very similar to those found for GABA itself and indicated no direct correlation with single subunit distributions for any of these compounds. Only the low-efficacy GABA mimetic 5-(4-piperidyl)isoxazol-3-ol (4-PIOL…

AgonistMalemedicine.medical_specialtyAgonist-antagonistmedicine.drug_classBiologyLigandsPartial agonistGABAA-rho receptorCell Linechemistry.chemical_compoundPiperidinesInternal medicinemedicineAnimalsHumansRats WistarReceptorGABA AgonistsPharmacologyIonophoresGABAA receptorBrainIsoxazolesBridged Bicyclo Compounds HeterocyclicReceptors GABA-ARatsEndocrinologyMuscimolchemistryThiomuscimolEuropean journal of pharmacology
researchProduct

Synthesis and antimicrobial activity of new 3-(1-R-3(5)-methyl-4-nitroso-1H-5(3)-pyrazolyl)-5-methylisoxazoles.

2000

A number of new 3-(1-R-3(5)-methyl-4-nitroso-1H-5(3)-pyrazolyl)-5-methylisoxazoles 6a-g (7b-f) were synthesized and tested for antibacterial and antifungal activity. Some of these compounds displayed antifungal activity at non-cytotoxic concentrations. Derivative 6c was 9 times more potent in vitro than miconazole and 20 times more selective against C. neoformans. 6c was also 8- and 125-fold more potent than amphotericin B and fluconazole, respectively. None of the compounds was active against bacteria. Preliminary structure-activity relationship (SAR) studies showed that the NO group at position 4 of the pyrazole ring is essential for the activity. Lipophilicity of the pyrazole moiety, N-a…

Antifungal AgentsStereochemistryClinical BiochemistryPharmaceutical ScienceMicrobial Sensitivity TestsPyrazoleGram-Positive BacteriaBiochemistryChemical synthesischemistry.chemical_compoundStructure-Activity RelationshipAnti-Infective AgentsDrug DiscoveryGram-Negative BacteriamedicineMoietyHumansCytotoxicityMolecular BiologyChemistryOrganic ChemistryFungiNitrosoIsoxazolesAntimicrobialAnti-Bacterial AgentsLipophilicityCryptococcus neoformansHIV-1Molecular MedicineMiconazolemedicine.drugBioorganicmedicinal chemistry
researchProduct

Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy) pyrazole derivatives

2011

The antibacterial and antifungal activity of a series of products, in which the 1,5-dimethyl-4-(cyano- NNO-azoxy)pyrazol-3-yl and 1,3-dimethyl-4-(cyano-NNO-azoxy)pyrazol-5-yl moieties were linked to pyridine, pyrazole, isoxazole, thiophene and the furan ring, were examined. No molecule displayed activity against the Gram-negative bacteria tested. Conversely, some compounds displayed activity against two Staphylococcus aureus strains, including the methicillin resistant strain. All compounds displayed interesting antifungal activity, the most active compound of the series being the thiophene derivative 7a. This compound’s activity against Candida krusei and Candida glabrata (MIC = 0.25 and 0…

AzoxyStaphylococcus aureusAntifungal AgentsStereochemistryClinical BiochemistryPharmaceutical ScienceMicrobial Sensitivity TestsPyrazoleBiochemistryChemical synthesisAntifungal activity Pyrazole Azole sistance Cyano-NNO-azoxy Thiophenechemistry.chemical_compoundAnti-Infective AgentsThiopheneCandida kruseiNitrilesDrug DiscoveryThiopheneAntifungal activityIsoxazoleAntifungal activity; Pyrazole; Azole resistance; Cyano-NNO-azoxy; Thiophene.Molecular BiologyCandidaMolecular StructurebiologyCandida glabrataOrganic ChemistryBiological activitybiology.organism_classificationSettore CHIM/08 - Chimica FarmaceuticachemistryCyano-NNO-azoxyPyrazoleAzole resistancePyrazolesMolecular MedicineAzo Compounds
researchProduct